Vision and strategy


AlzeCure’s vision is to become the leading research company developing groundbreaking drugs for Alzheimer’s, pain and other serious diseases with high unmet medical need.


AlzeCure Pharma’s strategy is to develop a broad portfolio of symptomatic, disease-modifying and preventive drugs for Alzheimer’s, pain and other serious illnesses through work based on the following four guidelines:

  • The right patient: Focusing on genetically, clinically and pathologically defined diseases to increase the ability of clinical effect.
  • The right mechanism: The treatment acts on genetically associated signal pathways in Alzheimer’s disease and other indications.
  • The right clinical testing: The clinical studies are based on validated biomarkers and preclinical methods with good translation to humans.
  • The right treatment: Small-molecule drugs that penetrate the blood brain barrier (BBB) and which are designed for safe, efficacious long-term treatment.

AlzeCure is evaluating possibilities for future collaboration agreements and commercial licensing agreements with leading pharmaceutical companies that can contribute R&D, manufacturing, commercialization and geographical reach to enhance the value of the Company’s drug platforms and drug candidates.